SORLA is a protein trafficking receptor that has been mainly studied in neurons, but it also plays a role in cancer cells. Professor Johanna Ivaska's research group at Turku Bioscience observed that SORLA functionally contributes to the most reported therapy-resistant mechanism by which the cell-surface receptor HER3 counteracts HER2 targeting therapy in HER2-positive cancers. Removing […]
MRNA VS. CONVENTIONAL VACCINES Meet our new Chief Patient Officer, Dr. Dara Richardson-Heron Working Together to Empower Women Pfizer Women’s Resource Group Universal vs. Single Payer Healthcare Until the 20th century, breast cancer was considered an unspeakable condition, and in general, cancer was seen as an incurable disease.1 Thanks to increases in funding, research, and […]
The plasmaMATCH trial has given the strongest evidence yet that the “liquid biopsies” are reliable enough to be offered to patients on the NHS once it has passed approval. The move raises the prospect of a major overhaul of patient care that could get them the best available drugs more rapidly than at present. Study […]
